Company Filing History:
Years Active: 2013-2016
Title: **Innovative Breakthroughs by Inventor Qin Jiang in Cancer Resistance Treatments**
Introduction
Qin Jiang is an accomplished inventor based in Memphis, TN, recognized for his significant contributions to the field of cancer treatment. With a total of two patents, his work aims to address critical challenges in treating cancers that exhibit resistance to existing therapeutic interventions.
Latest Patents
Qin Jiang’s latest patents focus on "Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors." These patents detail compositions and methods designed for diagnosing and treating cancers that resist at least one ALK kinase inhibitor. The inventions are predicated on the identification of mutations within the ALK gene, which confer resistance to these inhibitors. Furthermore, the patents describe polynucleotides and polypeptides that possess ALK inhibitor resistance mutations, which serve as valuable tools in diagnostic and therapeutic applications for diseases linked to abnormal ALK activity, particularly cancers that evade treatment by ALK kinase inhibitors. In addition, methods and compositions for identifying agents that inhibit the activity of ALK resistance mutants are also outlined in these patents.
Career Highlights
Currently, Qin Jiang is associated with St. Jude Children's Research Hospital, where his innovative research contributes to developing novel therapeutic strategies for challenging cancer types. His commitment to improving patient outcomes through research has established him as a vital asset in the medical research community.
Collaborations
Throughout his career, Qin Jiang has collaborated with notable colleagues, including Stephan W. Morris and Xiaoli Cui. These collaborations enhance the breadth of research and innovation in the field of cancer treatment, allowing for a multidimensional approach to tackling complex medical challenges.
Conclusion
Qin Jiang’s contributions to cancer treatment through his patents underscore the importance of innovation in the medical field. His research, particularly in discovering mutations that lead to resistance against ALK kinase inhibitors, has the potential to significantly improve diagnostic and therapeutic strategies for patients worldwide. His continued work at St. Jude Children's Research Hospital remains instrumental in advancing science and enhancing patient care in oncology.